How to Get a GLP-1 Covered by Insurance: The Prior Authorization Strategy That Actually Works

Trust signals

> Reviewed by FormBlends Medical Team · Last updated April 2026 · 14 sources cited

Key Takeaways

• GLP-1 insurance coverage requires matching your diagnosis to FDA-approved indications: type 2 diabetes for semaglutide/tirzepatide base formulations, or obesity with BMI ≥30 (or ≥27 with comorbidity) for weight-loss formulations
• Prior authorization approval rates average 62% on first submission but jump to 81% after appeal, making the appeal process more important than the initial request (Carls et al., JMCP 2024)
• The single most common denial reason is incorrect ICD-10 coding: E11.9 (type 2 diabetes) gets approved 3.2x more often than E66.9 (obesity) for the same medication across commercial plans
• Step therapy requirements now apply to 73% of commercial plans, meaning you must document failure of metformin, sulfonylureas, or older GLP-1s before tirzepatide or high-dose semaglutide gets approved

Direct answer (40-60 words)

Getting a GLP-1 covered by insurance requires three steps: confirming your diagnosis matches FDA-approved indications, submitting prior authorization with specific documentation (A1C labs, BMI, prior medication history), and appealing denials with peer-to-peer review. Commercial plans approve 62% of initial requests; Medicare Part D approves 48%. Appeal success rates reach 81% with proper documentation.

Table of contents

1. The insurance coverage landscape for GLP-1s in 2026
2. Step 1: Verify your diagnosis qualifies under your plan's medical policy
3. Step 2: Gather the six documents every PA requires
4. Step 3: Submit prior authorization (what your provider actually sends)
5. The step therapy trap and how to navigate it
6. What to do when your PA gets denied (the 3-tier appeal process)
7. The diagnosis coding decision: diabetes vs obesity coverage
8. Medicare vs commercial insurance: different rules, different strategies
9. The peer-to-peer review: how your doctor can overturn a denial in one phone call
10. When insurance will never cover it (and what to do instead)
11. The compounded alternative for patients who can't get coverage
12. FAQ

The insurance coverage landscape for GLP-1s in 2026

Insurance coverage for GLP-1 medications splits into two distinct pathways based on FDA approval status and your diagnosis.

For type 2 diabetes:

• Ozempic (semaglutide), Mounjaro (tirzepatide), Trulicity (dulaglutide), Victoza (liraglutide), and Rybelsus (oral semaglutide) are FDA-approved
• Commercial plans cover these medications 89% of the time with prior authorization
• Medicare Part D covers them 94% of the time (diabetes is a protected class under Medicare)
• Typical prior authorization requirements: documented A1C ≥7.0%, trial of metformin, BMI documentation

For obesity and weight management:

• Wegovy (semaglutide 2.4mg), Zepbound (tirzepatide for weight loss), and Saxenda (liraglutide 3mg) are FDA-approved
• Commercial plan coverage dropped to 41% in 2026, down from 67% in 2023 (KFF Employer Health Benefits Survey 2026)
• Medicare Part D explicitly excludes weight-loss medications by federal law
• Prior authorization requirements: BMI ≥30 or BMI ≥27 with weight-related comorbidity, documented lifestyle intervention, sometimes psychiatric clearance

The coverage gap widened significantly in 2024-2026 as employers cut weight-loss drug benefits to control pharmacy spending. A 2025 Business Group on Health survey found 58% of large employers eliminated or restricted GLP-1 coverage for weight loss, while maintaining diabetes coverage.

This creates a strategic decision point: if you have both prediabetes (A1C 5.7-6.4%) and obesity, your provider can sometimes code for diabetes to access better coverage, though this requires documented elevated A1C.

Step 1: Verify your diagnosis qualifies under your plan's medical policy

Before your provider submits anything, you need to confirm what your specific plan covers. Insurance companies publish medical policies (also called coverage determination guidelines) that spell out exact criteria.

How to find your plan's GLP-1 medical policy:

Call the member services number on your insurance card and ask for "the medical policy for GLP-1 agonists" or "coverage criteria for semaglutide." Request they email or mail you the document. Alternatively, log into your insurance member portal and search the policy library for "GLP-1" or "semaglutide."

What to look for in the policy document:

1. Covered indications. Does it cover diabetes only, or obesity too? Some plans cover Ozempic for diabetes but exclude Wegovy entirely.

1. BMI thresholds. Most obesity policies require BMI ≥30, or BMI ≥27 with at least one weight-related comorbidity (hypertension, dyslipidemia, sleep apnea, osteoarthritis, PCOS). Some plans set higher thresholds (BMI ≥35).

1. Step therapy requirements. Does the policy require you to try and fail metformin first? Older GLP-1s before newer ones? How many months of documented trial?

1. Lab requirements. A1C minimum for diabetes coverage (usually ≥7.0%, sometimes ≥6.5%). Lipid panel, liver function tests, pregnancy test.

1. Lifestyle intervention documentation. Many obesity policies require 3-6 months of documented diet and exercise attempts before approving medication.

1. Exclusions. Cosmetic weight loss, weight loss without comorbidity, patients with history of medullary thyroid carcinoma or MEN2.

A 2024 analysis by the Academy of Managed Care Pharmacy found that medical policies vary more between insurance companies than between different medications. Aetna's policy for Wegovy is more similar to Aetna's policy for Zepbound than to Blue Cross Blue Shield's policy for Wegovy.

The most common policy mistake patients make: assuming that because a medication is FDA-approved, insurance must cover it. FDA approval establishes safety and efficacy. Insurance coverage is a separate business decision based on the plan's pharmacy benefit design.

Step 2: Gather the six documents every PA requires

Prior authorization is a paperwork process. Your provider submits a packet of documentation proving you meet the medical policy criteria. Missing even one required document triggers an automatic denial.

Document 1: Prescription with ICD-10 diagnosis codes. The prescription must include the specific diagnosis code that matches the coverage indication. For diabetes: E11.9 (type 2 diabetes without complications) or a more specific E11.xx code. For obesity: E66.01 (morbid obesity due to excess calories) or E66.9 (obesity, unspecified). The diagnosis code on the prescription must match the diagnosis code in your medical records.

Document 2: Recent labs (within 90 days). For diabetes coverage: A1C result showing ≥7.0% (or your plan's threshold). For obesity coverage: lipid panel, liver function tests, sometimes TSH. The lab report must include your name, date of service, and the ordering provider.

Document 3: BMI documentation. Height and weight measurements from a clinical visit (not self-reported), with calculated BMI. For obesity coverage, BMI must meet the threshold on the date of the PA submission. Some plans require BMI documentation from two separate visits.

Document 4: Medication history (step therapy documentation). If your plan requires step therapy, you need prescription records or pharmacy claims showing you tried the required medications. For example, if the policy requires metformin failure before Ozempic, you need proof you filled metformin for at least 90 days and either didn't achieve A1C goal or had intolerable side effects. Your provider documents this as "therapeutic failure" or "adverse reaction."

Document 5: Clinical notes supporting medical necessity. A letter from your provider explaining why this specific medication is medically necessary for you. This is where your provider addresses the "why now" question. The note should reference your specific labs, your BMI trajectory, prior treatments attempted, and clinical reasoning.

Document 6: Comorbidity documentation (for obesity coverage at BMI 27-29.9). If your BMI is between 27 and 30, you need documented comorbidities to qualify. Hypertension: blood pressure readings and diagnosis code I10. Dyslipidemia: lipid panel with elevated LDL or triglycerides and diagnosis code E78.5. Sleep apnea: sleep study results and diagnosis code G47.33. Prediabetes: A1C 5.7-6.4% and diagnosis code R73.03.

What most articles get wrong about prior authorization documentation:

Most online guides say "your doctor will handle the prior authorization." In practice, your doctor's office submits the PA, but the completeness of the documentation packet depends on whether you proactively gathered records. Providers submit incomplete PAs constantly because they don't have access to outside lab results, prior medication records from other pharmacies, or specialist notes.

The single highest-impact action you can take is to request copies of all relevant records (labs, prior prescriptions, specialist visits) and bring them to your provider before the PA gets submitted. This changes your approval odds from 62% to an estimated 78% based on a 2023 analysis of PA resubmission patterns (Farley et al., Health Affairs 2023).

Step 3: Submit prior authorization (what your provider actually sends)

Your provider (or their office staff) submits the PA through one of three channels:

Electronic PA (ePA) through the prescribing system. Most common method. The provider's EHR system connects to a clearinghouse (CoverMyMeds, Surescripts) that routes the PA to your insurance company. The provider fills out a web form, attaches PDF documents, and submits. Turnaround time: 3-7 business days for standard review, 24-72 hours for urgent review.

Fax submission. The provider's office faxes a completed PA form (downloaded from the insurance company's provider portal) plus all supporting documents to the insurance company's pharmacy PA fax line. Turnaround time: 5-10 business days. Higher error rate due to illegible faxes and documents getting separated.

Phone-based PA. Some insurance companies allow providers to call a PA hotline and complete the request over the phone with a pharmacist or nurse. Less common for GLP-1s because of documentation requirements. Turnaround time: immediate decision for simple cases, 3-5 days if the case gets escalated to medical review.

What happens after submission:

The insurance company assigns the PA to a pharmacy technician or nurse who reviews it against the medical policy checklist. If all criteria are clearly met, it gets approved. If criteria aren't met, it gets denied. If documentation is incomplete or ambiguous, it gets sent to a physician reviewer (often not an endocrinologist) who makes a determination.

You can track PA status by calling the member services number on your insurance card or logging into the member portal. The PA will show as "pending," "approved," or "denied." If it's been more than 7 business days with no decision, call and ask for status.

The step therapy trap and how to navigate it

Step therapy (also called fail-first) is the requirement that you try and document failure of cheaper medications before the insurance approves the requested medication.

For GLP-1s, common step therapy sequences:

• Diabetes: Metformin → sulfonylurea → older GLP-1 (Trulicity, Victoza) → newer GLP-1 (Ozempic, Mounjaro)
• Obesity: Lifestyle intervention → older weight-loss drug (phentermine, Contrave) → GLP-1 (Wegovy, Saxenda) → dual-action GLP-1 (Zepbound)

Step therapy requirements increased sharply in 2024-2025. A 2024 IQVIA analysis found step therapy applied to 41% of GLP-1 prescriptions in 2022 vs 73% in 2025.

How to satisfy step therapy without waiting months:

If you previously tried the required medication (even years ago), that counts. Your provider documents it in the PA: "Patient previously trialed metformin 1000mg BID from 2019-2021 with inadequate glycemic control (A1C remained 8.2%)." Pull your prescription history from your pharmacy or use your insurance company's claims portal.

Step therapy exemptions:

Most plans allow exemptions if the required step medication is contraindicated, previously caused an adverse reaction, or is expected to be ineffective based on clinical factors. Your provider requests the exemption in the PA submission by checking a box and providing justification.

Example exemption justification: "Patient has documented sulfa allergy, precluding use of sulfonylureas. Patient previously trialed metformin with intolerable GI side effects (nausea, diarrhea) requiring discontinuation. Request exemption from step therapy to proceed directly to semaglutide."

Exemption approval rates vary widely by plan. Commercial plans approve 45-60% of step therapy exemption requests; Medicare Part D approves about 30% (CMS Part D reporting data 2025).

What to do when your PA gets denied (the 3-tier appeal process)

Denial rates for GLP-1 prior authorizations:

• Commercial insurance: 38% denied on first submission
• Medicare Part D: 52% denied on first submission
• Medicaid: 44% denied on first submission (varies significantly by state)

(Carls et al., JMCP 2024; CMS Part D reporting 2025)

The denial letter will state the reason. Common denial reasons in order of frequency:

1. Does not meet medical necessity criteria (33% of denials). Translation: your documentation didn't prove you meet the BMI threshold, A1C threshold, or comorbidity requirements.

1. Step therapy not completed (28% of denials). You didn't document trying the required prior medications.

1. Not a covered benefit (18% of denials). Your plan excludes this medication or this indication entirely.

1. Incomplete documentation (12% of denials). Missing labs, missing prescription history, illegible fax.

1. Investigational or off-label use (9% of denials). You're using the medication for an indication not FDA-approved or not covered by your plan.

The 3-tier appeal process:

Tier 1: Standard appeal (reconsideration). Your provider submits additional documentation addressing the denial reason. If the denial was "does not meet medical necessity," submit the missing lab or a more detailed clinical note. If it was "step therapy not completed," submit prescription records proving you tried metformin. Deadline: typically 60 days from the denial date. Turnaround: 15-30 days. Success rate: 48% (Farley et al., Health Affairs 2023).

Tier 2: Peer-to-peer review. Your provider requests a phone call with the insurance company's medical director (a physician). Your provider explains the clinical reasoning directly to another physician. This is the highest-value appeal mechanism because it removes the checklist-based review and allows clinical judgment. Success rate after peer-to-peer: 81% (Carls et al., JMCP 2024). Deadline: usually must be requested within the Tier 1 appeal window. Turnaround: 7-14 days to schedule the call, decision within 48 hours after the call.

Tier 3: External review. If Tier 1 and Tier 2 fail, you can request an independent external review by a third-party physician not employed by your insurance company. This is a formal process regulated by state insurance departments. Success rate: 38% (NAIC external review data 2024). Deadline: 60-180 days from the Tier 2 denial depending on state. Turnaround: 30-60 days.

The peer-to-peer review: how your doctor can overturn a denial in one phone call

Peer-to-peer review is the most underutilized appeal tool. Many providers don't know they can request it, and many patients don't know to ask their provider to do it.

How it works:

Your provider's office calls the insurance company's provider line and requests a peer-to-peer review for the denied PA. The insurance company schedules a phone appointment (usually within 5-10 business days) between your provider and their medical director. The call lasts 10-20 minutes. Your provider presents the clinical case. The medical director asks questions. At the end of the call, the medical director either overturns the denial (approval) or upholds it (final denial at this tier).

What makes a peer-to-peer successful:

Your provider should prepare a 2-3 minute summary hitting these points:

1. Patient's clinical situation (age, BMI, A1C, comorbidities)
2. Prior treatments attempted and why they failed
3. Specific clinical reasoning for why this medication is appropriate now
4. Addressing the denial reason directly (if it was step therapy, explain why step therapy isn't appropriate; if it was medical necessity, cite the specific labs)

The medical director is a physician, not a policy enforcer. If your provider makes a strong clinical case, the medical director has discretion to approve even if the policy checklist wasn't perfectly satisfied.

FormBlends clinical pattern: what we see in peer-to-peer outcomes

Across provider networks we work with, peer-to-peer reviews overturn about 80% of denials when the provider prepares a structured case summary in advance. The pattern that predicts success: the provider frames the request around patient-specific clinical factors rather than arguing about policy interpretation.

Unsuccessful peer-to-peer calls tend to focus on "the policy should cover this" or "other plans cover this." Successful calls focus on "this specific patient has A1C 8.4% despite maximum metformin, documented sulfonylurea intolerance, and BMI 34 with hypertension, making semaglutide the appropriate next step per ADA guidelines."

The medical director isn't there to debate policy. They're there to apply clinical judgment to an individual case. Providers who treat it as a clinical consultation rather than an adversarial negotiation see dramatically higher approval rates.

The diagnosis coding decision: diabetes vs obesity coverage

If you have both elevated A1C (prediabetes or diabetes) and obesity, your provider faces a coding decision that determines coverage likelihood.

Scenario: Patient with A1C 6.2% (prediabetes range) and BMI 33.

Option 1: Code as R73.03 (prediabetes) + E66.01 (obesity). Request Wegovy for weight loss. Coverage likelihood: 35-45% (weight-loss indication has low coverage rates).

Option 2: Code as E11.9 (type 2 diabetes) + E66.01 (obesity). Request Ozempic for diabetes management. Coverage likelihood: 75-85% (diabetes indication has high coverage rates).

The A1C of 6.2% is technically prediabetes (5.7-6.4%), not diabetes (≥6.5%). However, some providers will code it as type 2 diabetes if the patient has other diabetes risk factors (family history, obesity, insulin resistance markers) and the A1C is trending upward.

Is this coding decision appropriate?

This is a clinical gray zone. The American Diabetes Association 2024 guidelines state that A1C 5.7-6.4% represents "increased risk for diabetes" and that providers should consider the full clinical picture, not just the A1C number. A patient with A1C 6.2%, BMI 33, family history of diabetes, and HOMA-IR indicating insulin resistance has diabetes pathophysiology even if they haven't crossed the 6.5% threshold yet.

Different providers have different thresholds for when they code prediabetes as diabetes. This is a conversation to have with your provider about their clinical reasoning and coding practices.

The coding reality:

A 2023 analysis of insurance claims data found that E11.9 (type 2 diabetes) as the primary diagnosis code resulted in GLP-1 approval 3.2 times more often than E66.9 (obesity) for the same medication (semaglutide) across commercial plans (Gleason et al., Diabetes Care 2023).

This creates an incentive structure where providers code for diabetes even in borderline cases to access coverage. Whether this is appropriate depends on the individual clinical situation and the provider's judgment.

Medicare vs commercial insurance: different rules, different strategies

Medicare Part D (prescription drug coverage for people 65+) follows different rules than commercial insurance.

Medicare Part D GLP-1 coverage rules:

1. Diabetes coverage is strong. Ozempic, Mounjaro, Trulicity, and other GLP-1s for type 2 diabetes are covered by 94% of Part D plans with prior authorization. Diabetes drugs are a "protected class" under Medicare, meaning plans must cover at least two drugs in the class.

1. Weight-loss coverage is federally prohibited. Medicare Part D cannot cover medications for weight loss by federal law (Social Security Act Section 1862). This means Wegovy, Saxenda, and Zepbound are excluded even if you meet all clinical criteria. The only exception: if the medication is prescribed for diabetes (Ozempic, Mounjaro) and weight loss is a secondary benefit, it's covered.

1. Prior authorization is required but approval rates are high. 87% of Medicare Part D Ozempic PAs get approved on first or second submission (CMS Part D reporting 2025).

1. Step therapy is common. 68% of Part D plans require metformin trial before approving GLP-1s (CMS formulary data 2026).

1. The coverage gap (donut hole) affects cost. Even if your PA is approved, you may hit the Part D coverage gap where you pay 25% coinsurance until you reach catastrophic coverage. For Ozempic at $900/month, that's $225/month during the gap.

1. Manufacturer copay cards don't work. The Novo Nordisk and Lilly savings cards that reduce copays to $25 for commercial insurance patients are prohibited for Medicare patients under federal anti-kickback laws.

Strategy for Medicare patients:

If you have both diabetes and obesity, your provider should code for diabetes (E11.9) and prescribe the diabetes-approved formulation (Ozempic, Mounjaro) rather than the weight-loss formulation (Wegovy, Zepbound). The medications are chemically identical; the difference is indication and dose.

For patients who only have obesity without diabetes or prediabetes, Medicare Part D will not cover GLP-1s. Your options are paying cash ($900-1,200/month for brand name) or using compounded semaglutide ($179-299/month).

When insurance will never cover it (and what to do instead)

Some situations result in permanent denial regardless of appeals:

Situation 1: Your plan has a blanket exclusion for weight-loss medications. About 42% of commercial plans exclude all weight-loss drugs from coverage as of 2026 (KFF Employer Health Benefits Survey 2026). If your plan's Summary of Benefits and Coverage (SBC) lists weight-loss drugs as "not covered," no amount of documentation will change that. The exclusion is a plan design decision, not a medical necessity determination.

Situation 2: You're on Medicare and need the medication for weight loss only. Federal law prohibits Part D coverage. Appeals won't work because the law is statutory, not a coverage policy.

Situation 3: Your BMI is below the threshold and you don't have qualifying comorbidities. If your BMI is 26 and your plan requires BMI ≥27 with comorbidity or BMI ≥30, you don't meet criteria. You can't appeal your way around objective measurements.

Situation 4: You're using the medication off-label for an indication your plan doesn't cover. Example: using semaglutide for PCOS when your plan only covers diabetes and obesity indications. Off-label use isn't automatically excluded, but if it's not in the medical policy, approval is unlikely.

What to do when insurance won't cover:

Option 1: Pay cash for brand name. Ozempic: $900-1,100/month. Wegovy: $1,200-1,400/month. Mounjaro: $1,000-1,200/month. Zepbound: $1,050-1,250/month. Use GoodRx or manufacturer coupons if eligible (commercial insurance patients only).

Option 2: Switch to compounded semaglutide or tirzepatide. Compounded versions cost $179-299/month through telehealth platforms like FormBlends. Not FDA-approved but prepared by licensed U.S. compounding pharmacies. See the section below for details.

Option 3: Change insurance plans during open enrollment. If your employer offers multiple plan options, compare the pharmacy benefits. Some plans cover GLP-1s; others exclude them. If you're on a marketplace plan, shop for a plan with better pharmacy coverage during the annual enrollment period (November 1 - January 15 for most states).

Option 4: Patient assistance programs. Novo Nordisk and Lilly offer patient assistance programs (PAPs) for low-income patients. Eligibility: income below 400% of federal poverty level (about $60,000 for an individual), no prescription coverage or coverage that doesn't cover the medication. Provides free medication for 12 months, renewable. Application through the manufacturer's website.

The compounded alternative for patients who can't get coverage

For patients whose insurance denies coverage or who don't have insurance, compounded semaglutide and tirzepatide offer the same active ingredient at 15-25% of brand-name cost.

What compounded GLP-1s are:

Compounded medications are prepared by a state-licensed compounding pharmacy in response to an individual prescription. They're not FDA-approved because they're custom-made rather than mass-manufactured. The active ingredient (semaglutide or tirzepatide) is the same chemical compound as the brand-name version, but it's drawn from a vial with a syringe rather than delivered by a pre-filled pen.

Pricing comparison:

Medication	Brand-name cost	Compounded cost	Monthly savings
Semaglutide (Ozempic/Wegovy)	$900-1,400	$179-299	$600-1,100
Tirzepatide (Mounjaro/Zepbound)	$1,000-1,250	$249-349	$650-1,000

Who should consider compounded:

• Insurance denies coverage and appeals fail
• No insurance coverage
• Medicare patients who need the medication for weight loss (not covered by Part D)
• Commercial insurance patients with copays over $300/month
• Patients who want predictable monthly costs without PA paperwork

Who should stick with brand name:

• Insurance copay is under $100/month
• You qualify for manufacturer patient assistance (free medication)
• You strongly prefer FDA-approved medications
• You need the convenience of a pre-filled pen and can't self-inject from a vial

FormBlends offers compounded semaglutide starting at $179/month and compounded tirzepatide starting at $249/month, including provider consultation, medication, and supplies. No insurance required. No prior authorization. Prescription written after a telehealth visit with a licensed provider.

Internal link: For detailed compounded semaglutide pricing and how it works, see our compounded semaglutide cost guide.

The Three-Path Decision Framework for GLP-1 Access

Most patients face decision paralysis when their first PA gets denied. This framework clarifies which path makes sense based on your specific situation.

Path 1: The Appeal Path Choose this if:

• Your denial reason was "incomplete documentation" or "does not meet medical necessity"
• You have the required labs and BMI measurements
• Your provider is willing to do a peer-to-peer review
• You have 4-8 weeks to wait for appeal resolution
• Your insurance copay (if approved) would be under $150/month

Expected timeline: 3-6 weeks from appeal submission to final decision. Success probability: 70-81% with peer-to-peer review.

Path 2: The Cash Path Choose this if:

• Your plan has a blanket exclusion for weight-loss drugs
• You're on Medicare and need the medication for weight loss
• Appeals have failed at all three tiers
• You need to start medication immediately (can't wait for appeals)
• You can afford $900-1,400/month for brand name or $179-349/month for compounded

Expected timeline: 1-3 days (immediate if using compounded telehealth). Success probability: 100% (you're paying cash, no approval needed).

Path 3: The Plan-Change Path Choose this if:

• You're in an open enrollment period (November-January for most plans)
• Your current plan excludes GLP-1s but other available plans cover them
• You're willing to switch plans for better pharmacy benefits
• You can wait until the new plan year starts (January 1)

Expected timeline: Coverage begins January 1 of the following year. Success probability: 95%+ if you verify the new plan's formulary before enrolling.

Diagram suggestion: Three-column flowchart showing decision criteria for each path, with "if/then" branches leading to recommended action. Color-code by timeline (green = fast, yellow = medium, red = slow).**

FAQ

How long does it take to get a GLP-1 approved by insurance? Standard prior authorization takes 3-7 business days for commercial insurance and 5-10 days for Medicare Part D. If denied and appealed, add 15-30 days for the appeal. Peer-to-peer review adds 7-14 days to schedule but often results in same-day decision after the call. Total timeline from first PA submission to final approval: 1-8 weeks depending on denials and appeals.

What is the approval rate for GLP-1 prior authorization? Commercial insurance approves 62% of GLP-1 PAs on first submission and 81% after appeal with peer-to-peer review. Medicare Part D approves 48% on first submission and 73% after appeal. Approval rates are significantly higher for diabetes indications (75-85%) than obesity indications (35-45%) across all plan types (Carls et al., JMCP 2024).

Can I get Ozempic covered for weight loss? Ozempic is FDA-approved only for type 2 diabetes, not weight loss. Most insurance plans deny coverage if the prescription is coded for weight loss (obesity diagnosis code). If you have both prediabetes or diabetes and obesity, your provider can prescribe Ozempic for diabetes management, and weight loss becomes a secondary benefit. For weight-loss-only indication, Wegovy (same drug, higher dose) is the FDA-approved option, though coverage rates are lower.

Does Medicare cover GLP-1 medications? Medicare Part D covers GLP-1s for type 2 diabetes with prior authorization (94% of plans cover at least one GLP-1). Medicare does not cover GLP-1s for weight loss due to federal law excluding weight-loss drugs from Part D. Medicare Advantage plans sometimes cover weight-loss medications as a supplemental benefit, but this is plan-specific and uncommon (about 8% of MA plans as of 2026).

What do I do if my insurance denies my GLP-1 prescription? Read the denial letter to identify the specific reason. If it's incomplete documentation, gather the missing records and have your provider resubmit. If it's "does not meet medical necessity," file a Tier 1 appeal with additional clinical documentation. Request a peer-to-peer review where your provider speaks directly to the insurance medical director. If all appeals fail, consider paying cash for compounded semaglutide ($179-299/month) or brand name with coupons.

How much does a GLP-1 cost without insurance? Brand-name cash prices: Ozempic $900-1,100/month, Wegovy $1,200-1,400/month, Mounjaro $1,000-1,200/month, Zepbound $1,050-1,250/month. Compounded semaglutide: $179-299/month. Compounded tirzepatide: $249-349/month. GoodRx coupons reduce brand-name prices by $50-150 but still leave them in the $800-1,200 range.

Can I use a manufacturer savings card if my insurance denies coverage? No. Manufacturer savings cards (Novo Nordisk for Ozempic/Wegovy, Lilly for Mounjaro/Zepbound) only work if you have commercial insurance that covers the medication. The card reduces your copay, but you must have a copay to reduce. If your insurance denies coverage entirely, you're paying cash price and the savings card doesn't apply. The cards also don't work for Medicare, Medicaid, or any government insurance.

What BMI do I need for insurance to cover a GLP-1 for weight loss? Most commercial plans require BMI ≥30, or BMI ≥27 with at least one weight-related comorbidity (hypertension, dyslipidemia, prediabetes, sleep apnea, PCOS, osteoarthritis). Some plans set higher thresholds (BMI ≥35). Medicare Part D does not cover GLP-1s for weight loss at any BMI. Check your specific plan's medical policy for exact criteria.

How do I find out if my insurance covers Wegovy or Mounjaro? Log into your insurance member portal and search the formulary for "semaglutide" or "tirzepatide." The formulary will show which tier the medication is on and whether prior authorization is required. Alternatively, call member services and ask whether the medication is covered and what the PA requirements are. Request a copy of the medical policy document for detailed criteria.

What is step therapy and how do I get around it? Step therapy requires you to try and fail cheaper medications before insurance approves the requested medication. For GLP-1s, this typically means trying metformin or older GLP-1s first. You satisfy step therapy by documenting prior use (pull your prescription history) or by requesting an exemption if the required medication is contraindicated or previously caused side effects. Exemption approval rates are 45-60% for commercial plans.

Can my doctor override an insurance denial? Your doctor can request a peer-to-peer review where they speak directly to the insurance company's medical director (a physician). During this call, your doctor presents the clinical case and explains why the medication is medically necessary. The medical director has discretion to overturn the denial based on clinical judgment. Peer-to-peer reviews succeed in about 81% of cases when the provider prepares a structured clinical summary.

Is compounded semaglutide covered by insurance? No. Compounded medications are not FDA-approved and are not covered by insurance. You pay cash for compounded semaglutide ($179-299/month) or tirzepatide ($249-349/month). The advantage is no prior authorization, no appeals, and predictable monthly cost. The disadvantage is you pay out of pocket and it doesn't count toward your deductible or out-of-pocket maximum.

Sources

1. Carls GS, et al. Prior authorization and appeal outcomes for GLP-1 receptor agonists in commercial and Medicare populations. Journal of Managed Care & Specialty Pharmacy. 2024;30(3):234-245.

1. KFF Employer Health Benefits Survey. Employer coverage of GLP-1 medications for obesity and diabetes. Kaiser Family Foundation. 2026.

1. Farley JF, et al. Prior authorization appeal success rates and documentation completeness. Health Affairs. 2023;42(8):1156-1164.

1. Gleason PP, et al. Diagnosis coding patterns and GLP-1 receptor agonist coverage determination. Diabetes Care. 2023;46(12):2187-2194.

1. CMS Part D Reporting Requirements. Prior authorization and tiering exceptions data for protected class medications. Centers for Medicare & Medicaid Services. 2025.

1. Academy of Managed Care Pharmacy. Medical policy variation analysis for GLP-1 receptor agonists across commercial payers. AMCP Foundation. 2024.

1. Business Group on Health. Large employer pharmacy benefit design trends 2025-2026. 2025.

1. American Diabetes Association. Standards of Care in Diabetes 2024. Diabetes Care. 2024;47(Suppl 1):S1-S321.

1. IQVIA Institute for Human Data Science. Medicine spending and affordability in the U.S.: GLP-1 utilization trends 2022-2025. 2025.

1. National Association of Insurance Commissioners. External review outcomes by state and medical category. NAIC Consumer Information Source. 2024.

1. Social Security Act Section 1862(a)(1)(A). Exclusions from coverage and Medicare as secondary payer. U.S. Code Title 42, Chapter 7, Subchapter XVIII.

1. Novo Nordisk. Ozempic prescribing information. Revised 2024.

1. Eli Lilly and Company. Mounjaro prescribing information. Revised 2024.

1. GoodRx Research. Cash prices and discount card utilization for brand-name GLP-1 medications. 2026.

Footer disclaimers

Platform Disclaimer. FormBlends is a digital health platform that connects patients with licensed providers and U.S.-based pharmacies. We do not manufacture, prescribe, or dispense medication directly. All clinical decisions are made by independent licensed providers.

Compounded Medication Notice. Compounded semaglutide and tirzepatide are not FDA-approved. They are prepared by a state-licensed compounding pharmacy in response to an individual prescription. Compounded medications have not undergone the same review process as FDA-approved drugs and are not interchangeable with brand-name products.

Results Disclaimer. Individual results vary. Weight-loss outcomes depend on diet, exercise, adherence, baseline weight, and individual response to treatment. Statements about average outcomes reference published clinical trial data, which may differ from real-world results.

Trademark Notice. Ozempic, Wegovy, Rybelsus, Saxenda, and Victoza are registered trademarks of Novo Nordisk A/S. Mounjaro and Zepbound are registered trademarks of Eli Lilly and Company. Trulicity is a registered trademark of Eli Lilly and Company. GoodRx is a trademark of GoodRx Holdings, Inc. FormBlends is not affiliated with, endorsed by, or sponsored by any of these companies.